Please login to the form below

Not currently logged in
Email:
Password:

amyotrophic lateral sclerosis

This page shows the latest amyotrophic lateral sclerosis news and features for those working in and with pharma, biotech and healthcare.

FDA grants priority review to Biogen’s tofersen for genetic form of ALS

FDA grants priority review to Biogen’s tofersen for genetic form of ALS

The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for Biogen’s tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral ... sclerosis (ALS).

Latest news

More from news
Approximately 2 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    The Dementia Consortium funds research into novel targets and treatments for dementia including Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, plus Parkinson’s disease, amyotrophic lateral sclerosis and

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    In fact, this has helped our team of scientists at BenevolentBio establish a set of hypotheses for drug candidates for Amyotrophic Lateral Sclerosis (ALS), a form of Motor Neurone Disease.

  • Deal Watch July 2016 Deal Watch July 2016

    181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and generation skeletal muscle activators in amyotrophic lateral sclerosis.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

    The US-based pharmaceutical firm specialises in developing disease-modifying treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).

  • Biogen Idec appoints senior neuroscientists Biogen Idec appoints senior neuroscientists

    The two will help lead Biogen Idec's research efforts across neurodegenerative and neuroimmune diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). ... He was also professor of

  • Biogen Idec names ALS unit head Biogen Idec names ALS unit head

    Donald Johns joins from Novartis. Biogen Idec has named former Novartis scientist Dr Donald Johns as head of its innovation hub for amyotrophic lateral sclerosis (ALS).

  • Andrew Gengos joins ImmunoCellular as CEO Andrew Gengos joins ImmunoCellular as CEO

    ImmunoCellular will benefit from Gengos's experience in neuroscience during his time at Neuraltus, which specialises in therapies for neurodegenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The ALS patient journey

    Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ... That will be the start of ALS, but your doctor will want to rule out other things, for example, Parkinson’s disease or multiple sclerosis.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...